Nipro Corp, a leading Japanese company, operates in the healthcare industry, focusing on medical equipment and pharmaceutical products. With a diverse business model, Nipro Corp manufactures and sells various medical devices, including renal and infusion solutions, blood purification systems, and diabetes care products. Their pharmaceutical division is involved in the development and sales of generic drugs and therapeutic pharmaceuticals. Through strategic partnerships and acquisitions, Nipro Corp continues to expand its global presence and enhance its product offerings. As a renowned healthcare company, Nipro Corp remains committed to improving patient outcomes and contributing to the advancement of medical science worldwide.

Nipro Corp is primarily active in the healthcare industry.

The main competitors of Nipro Corp in the market include Medtronic, Becton, Dickinson and Company, Terumo Corporation, Abbott Laboratories, and Fresenius Medical Care.

Nipro Corp is a leading Japanese company in the healthcare sector. Founded in 1954, it has a rich history and strong background. Nipro Corp initially started as a manufacturer of medical devices, specializing in hypodermic needles and syringes. Over the years, the company expanded its product portfolio to include a wide range of medical equipment, pharmaceuticals, and renal products. Nipro Corp has established itself as a global player, serving healthcare professionals and patients worldwide. With a commitment to innovation and quality, Nipro Corp continues to contribute to the advancement of healthcare technologies and improve the lives of people globally.

Nipro Corp, a renowned company, has achieved several significant milestones throughout its history. The company has successfully established a global presence in the healthcare industry through its innovative solutions and dedication to excellence. Nipro Corp has made key advancements in the development of medical devices, pharmaceuticals, and renal products, positioning itself as a leader in these sectors. Furthermore, Nipro Corp has achieved notable accomplishments in expanding its market reach, enhancing its product portfolio, and fostering strategic collaborations. The company's commitment to continual growth and improvement has enabled it to leave a lasting impact on the healthcare field, making it a trusted and respected name in the industry.

Nipro Corp is primarily present in various countries and regions across the globe. The company has a strong international presence, with its main operations centered in Japan, its home country. Additionally, Nipro Corp actively conducts business in North America, Europe, Asia, and other parts of the world. With a diversified geographical reach, Nipro Corp aims to serve a wide range of customers and expand its market presence globally.

Nipro Corp is a leading company globally, known for its strong corporate philosophy and values. The company represents a commitment to innovation, quality, and sustainability in the healthcare industry. Nipro Corp aims to enhance patients' lives through advanced medical technologies, including dialysis products, medical devices, and pharmaceuticals. With a focus on patient-centric care, Nipro Corp strives to ensure the highest standards of safety, effectiveness, and affordability in their products. The company's core values emphasize integrity, teamwork, and social responsibility. Nipro Corp continuously endeavors to contribute to society and improve healthcare outcomes worldwide.

Analysts currently set an average price target of 1,470.84 JPY for the Nipro stock (median: 1,326.00 JPY), implying -7.5 % versus the latest price. The consensus is based on 9 analyst ratings.

Nipro Analyst Price Targets 2026

9 analysts currently rate the Nipro stock: 5 recommend buying, 3 holding and 1 selling. For 2026, analysts expect Nipro to generate revenue of 675.21 B JPY and earnings per share of 84.03 JPY.

Nipro Analyst Price Targets 2026

Converted at the current exchange rate, the Nipro share trades at 8.65 EUR (1,607.50 JPY).

The Nipro share (8086.T) is listed on 4 stock exchanges, including: Frankfurt (5FA.F), München (5FA.MU), Düsseldorf (5FA.DU).

The Nipro Corporation is a Japanese company that operates in various industries. Founded in 1954, the company has become a global player, offering a wide range of products and services. One of the company's main activities is the manufacturing of medical products. Thanks to advanced technology and extensive research and development, Nipro is able to offer its customers a variety of high-quality products that are used in both clinical and home environments. Nipro's medical products include infusion and dialysis devices, insulin pumps and injectors, blood glucose meters, catheters, stents, and other medical devices. Additionally, the company also offers a wide range of pharmaceutical products used to treat various diseases and ailments. In addition to healthcare, Nipro is also involved in other industries. For example, the company has a division for electronics products, including touchscreens, LED lighting technology, and energy storage systems. Here too, the company strives to develop innovative technologies and offer its customers high-quality products. Nipro is also active in the food industry, offering a wide range of natural foods and beverages. The company places special emphasis on sustainability and environmental friendliness, employing organic farming methods and resource-efficient production processes. Another important area for Nipro is environmental technology. The company develops and produces photovoltaic modules to harness renewable energies and water purification systems that enable sustainable water usage. In addition to product manufacturing, Nipro also provides consulting services to customers in various industries. The company supports its customers in the development of new products or services and helps optimize business processes. Overall, Nipro's business model is highly diversified, encompassing various industries and divisions. The company is committed to developing innovative technologies and offering its customers high-quality products and services. It also emphasizes sustainability and environmental friendliness, taking its responsibility towards society and the environment seriously.

The expected revenue of Nipro is 675.21 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Nipro is 15.47 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Nipro is currently 19.13. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Nipro stock.

The price-to-sales ratio (P/S) of Nipro is currently 0.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Nipro stock.

The Eulerpool Quality Score for Nipro is 5/10.

The ISIN of Nipro is JP3673600007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Nipro is 875746. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Nipro is 8086.T. The ticker symbol is used to trade Nipro shares on the stock exchange.

Over the past 12 months, Nipro paid a dividend of 23.00 JPY . This corresponds to a dividend yield of about 1.43 %. For the coming 12 months, Nipro is expected to pay a dividend of 46.23 JPY.

The current dividend yield of Nipro is 1.43 %.

Nipro pays a dividend, distributed in the months of , , , .

Nipro paid dividends every year for the past 29 years.

For the upcoming 12 months, dividends amounting to 46.23 JPY are expected. This corresponds to a dividend yield of 2.88 %.

Nipro is assigned to the 'Health' sector.

To receive the latest dividend of Nipro from amounting to 18 JPY, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Nipro distributed 18.5 JPY as dividends.

The dividends of Nipro are distributed in JPY.